CIDRAP newsletters options
Dengue cases in the Americas so far this year are outpacing last year's record activity.
Data on Salmonella and Campylobacter bacteria from people and food-producing animals show high levels of resistance to commonly used antibiotics.
Among adults 65 years and older, vaccine effectiveness was 54% in the first 7 to 59 days.
COVID-19 survivors whose symptoms had resolved in less than 4 weeks or at least 12 weeks had comparable small deficits in cognitive function.
Willingness to get their child vaccinated against Lyme was associated with higher parental education.
For the first time, the mid-season report from four VE networks covers both pediatric and adult age groups.
Of the 135 isolates, 55% were identified as containing multi-drug resistant E coli.
Researchers saw sustained efficacy against both severe and less severe symptoms.
Patients undergoing gastrointestinal surgery at safety net hospitals had a nearly 30% increased risk of SSIs compared with all hospitals.
The group settled on stronger wording to clarify advice for patients and simplify decisions for clinicians.
The authors found a 78% reduction in risk of hospitalization among patients who had 3 doses of vaccine as well as Paxlovid.
In March 2020, home deaths rose 8%, but only 6% in the most economically deprived patients.
Bacteriophage therapy helped suppress a recurring bloodstream infection that wasn't responding to antibiotics, but an immune response was too much to overcome.
The recommendation applies to people traveling to outbreak areas and others at extra risk from the virus.
There was also a lower 3-month mortality (31% vs 39%) for the antiplatelet-therapy group.
The first-in-class, novel antibiotic showed non-inferiority to the current standard-of-care gonorrhea treatment.
A systematic review and meta-analysis found that women with Staphylococcus aureus bacteremia had an 18% increased mortality risk compared with men.
The risk of all-cause mortality dropped even further among patients with a booster dose of vaccine
Sixteen countries are struggling to contain outbreaks of the deadly illness, and the ability to make more vaccine is limited to its sole manufacturer.
The step frees up more resources for the dengue outbreak, which has sickened more than 31,000 people so far.
